Follow PharmaTimes: News RSS, filter it, and define how you want to receive the news (via Email, RSS, Telegram, WhatsApp etc.) https://follow.it/pharmatimes-news-rss Sun, 04 Jun 2023 13:39:44 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMpZYlhnZs00YIeLGixeGJZp BI-1910 is now the second of the company's anti-tumour necrosis factor receptor 2 programmes to enter clinical development]]> Fri, 02 Jun 2023 14:00:47 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMpZYlhnZs00YIeLGixeGJZp https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMpZYlhnZs00YAm0QkxGtqLL The final draft guidance recommends rimegepant for adults who have at least four migraine attacks per month, but less than 15]]> Fri, 02 Jun 2023 13:56:16 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMpZYlhnZs00YAm0QkxGtqLL https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMr69TmQc3FqjgX50KYzL9tX Nitisinone capsules are indicated for patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine]]> Thu, 01 Jun 2023 13:10:23 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMr69TmQc3FqjgX50KYzL9tX https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMr69TmQc3Fqjovmyuk5fxzE Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services]]> Thu, 01 Jun 2023 13:01:25 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMr69TmQc3Fqjovmyuk5fxzE https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMqFltKGGQ1FSs4HQhe4ZUzd The neurological disease affects approximately 2.8 million people worldwide]]> Wed, 31 May 2023 13:37:29 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMqFltKGGQ1FSs4HQhe4ZUzd https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMptkFruciKQxEFW8UNEQjUn The inflammatory form of arthritis is estimated to affect nearly 38 million people worldwide]]> Wed, 31 May 2023 13:26:25 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMptkFruciKQxEFW8UNEQjUn https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMp8e1FtQixmdwSngkwrdsok The EMA's human medicines committee concluded that the benefits of Adakveo did not outweigh its risks]]> Tue, 30 May 2023 13:25:33 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMp8e1FtQixmdwSngkwrdsok https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMp8e1FtQixmdwpx5_w21kha The drug has already been approved for this indication in the EU, with regulatory reviews continuing elsewhere including in the US]]> Tue, 30 May 2023 13:17:01 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMp8e1FtQixmdwpx5_w21kha https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMrQfXJavXdT21e5jCclomp- Therapy has been developed for use among children and adolescents with growth hormone deficiency]]> Fri, 26 May 2023 13:05:11 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMrQfXJavXdT21e5jCclomp- https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMrQfXJavXdT220dX84dnP8Y Life Sciences Council meeting hosted by chancellor Jeremy Hunt has unfolded in Downing Street]]> Fri, 26 May 2023 13:02:21 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMrQfXJavXdT220dX84dnP8Y https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMqdWdnCIILxHtaXKMm36c-X The collaboration aims to develop novel preclinical models with a view to identifying new treatments]]> Thu, 25 May 2023 11:17:44 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMqdWdnCIILxHtaXKMm36c-X https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMqdWdnCIILxHlyOSYGFl6uu Tumour treatment among all phase 1a cohorts in were concluded with no safety concerns]]> Thu, 25 May 2023 11:13:54 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMqdWdnCIILxHlyOSYGFl6uu https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMojtkKY7OuclhtLdxSOwF-n Celadon will sell a minimum of £3m worth of the high-THC product over the next three years]]> Wed, 24 May 2023 13:28:43 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMojtkKY7OuclhtLdxSOwF-n https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMojtkKY7Ouclu4sICfMfkNm Vital data supports early intervention in order to treat chronic obstructive pulmonary disease]]> Wed, 24 May 2023 13:23:27 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMojtkKY7Ouclu4sICfMfkNm https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMq0Y9sFFhffSjHgrmwRGUK6 Vital financing will allow the company to build a pipeline of novel therapies targeting serious conditions]]> Tue, 23 May 2023 13:30:16 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMq0Y9sFFhffSjHgrmwRGUK6 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMq0Y9sFFhffSgC0qH-r7xlT Receptor antagonist AM1476 developed as an anti-fibrotic treatment for lung and skin disorders]]> Tue, 23 May 2023 13:28:03 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMq0Y9sFFhffSgC0qH-r7xlT https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMoDiAq4dDolIUQqW5gBv7mX Treatment involves early Alzheimer’s disease and will be potentially used across Great Britain]]> Mon, 22 May 2023 13:17:44 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMoDiAq4dDolIUQqW5gBv7mX https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMoDiAq4dDolIem6srrLMsqK ACD856 is the leading candidate therapy on the company’s NeuroRestore platform]]> Mon, 22 May 2023 13:11:42 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMoDiAq4dDolIem6srrLMsqK https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMqFenj374gYme-bbeigX9oC Treatment concerns up to 150,000 patients in England with chronic heart failure]]> Fri, 19 May 2023 12:37:06 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMqFenj374gYme-bbeigX9oC https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMqFenj374gYmdKEpFgimKzx Screening patients to assess their clopidogrel resistance status will allow for alternative treatments]]> Fri, 19 May 2023 12:34:33 +0200 https://api.follow.it/track-rss-story-click/v3/c-g1Pb4wqMqFenj374gYmdKEpFgimKzx